Opendata, web and dolomites
Horizon2020 projects coordinated by "KAROLINSKA INSTITUTET"
| # | ||||
|---|---|---|---|---|
| 1 | SMART2D A people-centred approach through Self-Management and Reciprocal learning for the prevention and management of Type-2-Diabetes | 2015 | 3˙344˙981.00 | 3˙344˙979.00 |
| 2 | GLIOVAC Validation of a conceptually new treatment for glioblastoma multiforme with an IP protected small molecule | 2015 | 149˙693.00 | 149˙693.00 |
| 3 | GUTILC3 Cell-cell interactions critical to ILC3 function in the human gut | 2015 | 173˙857.00 | 173˙857.00 |
| 4 | EDC-MIXRISK Integrating Epidemiology and Experimental Biology to Improve Risk Assessment of Exposure to Mixtures of Endocrine Disruptive Compounds | 2015 | 6˙223˙330.00 | 6˙223˙330.00 |
| 5 | VECTORIGAMI DNA Origami for drug delivery | 2015 | 173˙857.00 | 173˙857.00 |
| 6 | ALLELIC REGULATION Revealing Allele-level Regulation and Dynamics using Single-cell Gene Expression Analyses | 2015 | 1˙923˙060.00 | 1˙923˙060.00 |
| 7 | PROGSY Prosaposin and GPR37 in synucleinopathies | 2015 | 1˙950˙033.00 | 1˙950˙033.00 |
| 8 | RVD3-RAVIS Novel Resolvin D3: its Role and Actions in the Resolution of Aortic Valvular Inflammation and Stenosis | 2015 | 185˙857.00 | 185˙857.00 |
| 9 | SYDAD Synaptic Dysfunction in Alzheimer Disease | 2015 | 3˙846˙736.00 | 3˙846˙736.00 |
| 10 | CODIC COmmercializing first-in-class dCTPase Inhibitors for treatment of hematological Cancers | 2016 | 150˙000.00 | 150˙000.00 |
| 11 | BOOSTB4 Boost Brittle Bones Before Birth | 2016 | 8˙378˙755.00 | 6˙608˙754.00 |
| 12 | COSYN Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders | 2016 | 6˙000˙000.00 | 5˙925˙000.00 |
| 13 | DYNASPACER Molecular Mechanisms of Dynamic and Spatial Control of Eph Receptors clustering | 2016 | 185˙857.00 | 185˙857.00 |
| 14 | POLYDRUG DISCOVERY Discovery of anticancer polymeric drugs that mimic the action of TRAIL | 2016 | 173˙857.00 | 173˙857.00 |
| 15 | NORVAS Therapeutic and Biomarker Potential of long non-coding RNAs in Vascular Disease | 2016 | 1˙493˙125.00 | 1˙493˙125.00 |
| 16 | SMILED Skeletal Muscle Inflammation: ambivalent roles in Exercise and Diabetes | 2016 | 185˙857.00 | 185˙857.00 |
| 17 | SMARTCUBES An innovative class of nanoparticles (“SmartCubes”) for the targeted delivery of protein therapeutics | 2016 | 185˙857.00 | 185˙857.00 |
| 18 | PREVENTSTOCAN Understanding microbe-induced stomach cancer – the key to a workable strategy for worldwide prevention | 2016 | 1˙941˙531.00 | 1˙941˙531.00 |
| 19 | BORN-IMMUNE Shaping of the Human Immune System by Primal Environmental Exposures In the Newborn Child | 2016 | 1˙422˙338.00 | 1˙422˙338.00 |
| 20 | LOCOMOTORINTEGRATION Functional connectome of brainstem circuits that control locomotion | 2016 | 2˙500˙000.00 | 2˙500˙000.00 |
| 21 | TAROX Targeting oxidative repair proteins for treatment of cancer and inflammation | 2016 | 2˙279˙406.00 | 2˙279˙406.00 |
| 22 | TRANSREAD Restoration of tumor suppressor function by induction of translational read-through of premature termination codons - a strategy for improved cancer therapy | 2016 | 2˙480˙889.00 | 2˙480˙889.00 |
| 23 | EPISCOPE Reversing the epigenetic state of oligodendrocyte precursors cells in multiple sclerosis | 2016 | 1˙895˙155.00 | 1˙895˙155.00 |
| 24 | NEUROGENESIS Exploration and promotion of neurogenesis in the adult brain | 2016 | 2˙500˙000.00 | 2˙500˙000.00 |
| 25 | PERICYTESTROMA Pericyte-derived tumor stroma – a target for cancer therapy | 2016 | 185˙857.00 | 185˙857.00 |
| 26 | MICRO-MACRO-ILC Dissecting the human microbiota-macrophage-innate lymphoid cell crosstalk in the lung | 2016 | 185˙857.00 | 185˙857.00 |
| 27 | RAPID Chromatin dynamics resolved by rapid protein labeling and bioorthogonal capture | 2017 | 1˙846˙360.00 | 1˙846˙360.00 |
| 28 | TICKLE ME Self and others in the sensorimotor system: a computational neuroanatomy of sensory attenuation | 2017 | 173˙857.00 | 173˙857.00 |
| 29 | MULTIPLEMS Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine | 2017 | 15˙041˙259.00 | 14˙721˙453.00 |
| 30 | MULTI-SIP HYDROGEL A multifunctional self-immolative hydrogel for accelerating the healing of chronic wounds | 2017 | 173˙857.00 | 173˙857.00 |
| 31 | BETASCREEN Validation of an in vivo translational medicine approach for the treatment of diabetes and diabetes complications | 2017 | 149˙365.00 | 149˙365.00 |
| 32 | MITOMETHYLOME Mitochondrial methylation and its role in health and disease | 2017 | 1˙499˙999.00 | 1˙499˙999.00 |
| 33 | RNAATHD Development of a high-resolution method to monitor structural changes of regulatory RNAs and therapeutic oligo-nucleotides directly in-cell. | 2017 | 185˙857.00 | 185˙857.00 |
| 34 | NOVITREP Novel viral therapy through targeting DNA repair | 2017 | 150˙000.00 | 150˙000.00 |
| 35 | PAINCELLS Decomposition of pain into celltypes | 2017 | 2˙443˙952.00 | 2˙443˙952.00 |
| 36 | TGDNL Mechanisms of cellular fatty acid homeostasis | 2017 | 265˙059.00 | 265˙059.00 |
| 37 | CELLTRACK Cellular Position Tracking Using DNA Origami Barcodes | 2017 | 1˙923˙262.00 | 1˙923˙262.00 |
| 38 | HEPASPHER Mimicking liver disease and regeneration in vitro for drug development and liver transplantation | 2017 | 2˙413˙449.00 | 2˙413˙449.00 |
| 39 | RTCURE Rheuma Tolerance for Cure | 2017 | 13˙846˙865.00 | 6˙000˙000.00 |
| 40 | MIRA Characterizing Microbe-specific Immune Responses in the pathogenesis of Autoimmunity | 2017 | 173˙857.00 | 173˙857.00 |
| 41 | 5D HEART PATCH A Functional, Mature In vivo Human Ventricular Muscle Patch for Cardiomyopathy | 2017 | 2˙149˙227.00 | 2˙149˙227.00 |
| 42 | TRIBAL A TRranslational approach to Identify Biomarkers for Asthma and Lung function impairment | 2017 | 1˙500˙000.00 | 1˙500˙000.00 |
| 43 | GENOMIS Illuminating GENome Organization through integrated MIcroscopy and Sequencing | 2018 | 1˙499˙808.00 | 1˙499˙808.00 |
| 44 | MTDNA-CURE Treating mitochondrial disease caused by pathogenic mtDNA mutations | 2018 | 2˙500˙000.00 | 2˙500˙000.00 |
| 45 | NANO TRACTION Nano Traction | 2018 | 173˙857.00 | 173˙857.00 |
| 46 | SELFIEV2.0 Identifying the neuronal basis of self-concept in the human medial prefrontal and medial temporal brain regions | 2018 | 265˙059.00 | 265˙059.00 |
| 47 | PROMETHEUS Flame nanoengineering for antibacterial medical devices | 2018 | 1˙812˙500.00 | 1˙812˙500.00 |
| 48 | PREVENT RA Towards prevention of autoimmune diseases: the case of rheumatoid arthritis | 2018 | 2˙000˙000.00 | 2˙000˙000.00 |
| 49 | CLINGEN-PSYCHTX Identifying Clinical, Demographic, and Genomic Risk Factors for Treatment-Resistant Psychiatric Disorders | 2018 | 185˙857.00 | 185˙857.00 |
| 50 | SOLO Single cell omics of the Oligodendrocyte Lineage in develOpment and disease | 2018 | 173˙857.00 | 173˙857.00 |
| 51 | REPROGRAM-DIABETES In vivo drug discovery for cellular reprogramming to β-cells – towards a future regenerative therapy for diabetes | 2018 | 1˙999˙968.00 | 1˙999˙968.00 |
| 52 | NEVULA Understanding selective neuronal vulnerability in Alzheimer’s disease | 2018 | 247˙059.00 | 247˙059.00 |
| 53 | MEGAALS Unravelling the Interplay between Metabolism, Gut Microbiome and Adaptive Immunity in Amyotrophic Lateral Sclerosis | 2018 | 1˙499˙196.00 | 1˙499˙196.00 |
| 54 | IMMUNEDIVERSITY Defining of human adaptive immune gene diversity and its impact on disease | 2018 | 2˙500˙000.00 | 2˙500˙000.00 |
| 55 | TOPSPEC Next generation precision antibody profiling - from science fiction to reality | 2019 | 3˙991˙500.00 | 3˙991˙500.00 |
| 56 | TICK THANK Tick-borne encephalitis Targeted by Human Active NK cells | 2019 | 185˙857.00 | 185˙857.00 |
| 57 | CL_EXOCYTOSIS “Molecular dissection of cytotoxic lymphocyte exocytosis | 2019 | 173˙857.00 | 173˙857.00 |
| 58 | SELF-UNITY The Unity of the Bodily Self | 2019 | 2˙583˙560.00 | 2˙583˙560.00 |
| 59 | SKINTRMDEEP Tissue Resident Memory (Trm) CD8+ T cells: Genome-wide dissection of cellular differentiation and heterogeneity | 2019 | 173˙857.00 | 173˙857.00 |
| 60 | SCHIZTYPE Brain cell type-specific interactions and schizophrenia | 2019 | 2˙064˙414.00 | 2˙064˙414.00 |
| 61 | ARTSILK Novel approaches to the generation of artificial spider silk superfibers | 2019 | 2˙000˙000.00 | 2˙000˙000.00 |
| 62 | EPI4MS Targeting the epigenome: towards a better understanding of disease pathogenesis and novel therapeutic strategies in Multiple Sclerosis | 2019 | 1˙998˙798.00 | 1˙998˙798.00 |
| 63 | TERMINATOR Ribosomal frameshifts as a novel mechanism to control RNA turnover in stress | 2019 | 191˙852.00 | 191˙852.00 |
| 64 | PCINBC Plasma cell heterogeneity and dynamics in patient tumors | 2019 | 203˙852.00 | 203˙852.00 |
| 65 | BRAINTIME Molecular atlas of the brain across the human lifespan | 2020 | 4˙328˙051.00 | 4˙328˙051.00 |
| 66 | EYELETS A regenerative medicine approach in diabetes. | 2020 | 2˙500˙000.00 | 2˙500˙000.00 |
| 67 | ALERT Action Leveraging Evidence to Reduce perinatal morTality and morbidity in sub-Saharan Africa | 2020 | 3˙999˙976.00 | 3˙999˙976.00 |
| 68 | HEAP Human Exposome Assessment Platform | 2020 | 11˙996˙515.00 | 11˙996˙515.00 |
| 69 | VIVA Vaccine development against variable pathogens | 2020 | 1˙750˙000.00 | 1˙750˙000.00 |
| 70 | TROYCAN Redefining the esophageal stem cell niche – towards targeting of squamous cell carcinoma | 2020 | 1˙483˙389.00 | 1˙483˙389.00 |
| 71 | MACINNASH Revealing the contribution of liver macrophage populations to NASH in insulin resistance | 2020 | 1˙999˙781.00 | 1˙999˙781.00 |
| 72 | INPRESS International Pregnancy Safety Study | 2020 | 219˙875.00 | 219˙875.00 |
| 73 | SYNKIT Synthetic Natural Killer Cells for Immunotherapy | 2020 | 191˙852.00 | 191˙852.00 |
| 74 | GUT-SEQ Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease | 2020 | 1˙500˙000.00 | 1˙500˙000.00 |
| 75 | SCSC The molecular diversity of regeneration in the zebrafish spinal cord | 2020 | 191˙852.00 | 191˙852.00 |
| 76 | HUMANE Transcriptional characterization of human postnatal and adult neural progenitors and of the stem cell niches. | 2020 | 203˙852.00 | 203˙852.00 |
| 77 | IMAP Imaging tumor vessels as a marker for p53 mutation status in cancer | 2020 | 203˙852.00 | 203˙852.00 |
| 78 | MITAFTERVIT Unravelling maintenance mechanisms of immune tolerance after termination of venom immunotherapy by means of clonal mast cell diseases | 2020 | 191˙852.00 | 191˙852.00 |
More Horizon 2020 projects
The Institution KAROLINSKA INSTITUTET has been involved also in the following Horizon 2020 projects.
- EUROMIX (2015, participant)
- ULTRADIAN (2015, participant)
- AGEING WITH ELEGANS (2015, participant)
- SHIPS (2015, participant)
- DIAGORAS (2015, participant)
- B-CAST (2015, participant)
- MULTIMOT (2015, participant)
- GERMAGE (2015, participant)
- MOCHA (2015, participant)
- FORECEE (2015, participant)
- NOMORFILM (2015, participant)
- MDS-RIGHT (2015, participant)
- PROPAG-AGEING (2015, participant)
- BRIDGES (2015, participant)
- ATHLOS (2015, participant)
- EUROLEISH-NET (2015, partner)
- BONEPAIN (2015, participant)
- CHROMATIN3D (2015, participant)
- BRAINVIEW (2015, participant)
- MIND (2015, participant)
- ZENCODE-ITN (2015, participant)
- EURO-HEALTHY (2015, participant)
- EMI-TB (2015, participant)
- RETHRIM (2015, participant)
- EUROSTEMCELL (2015, participant)
- SCI-GAIA (2015, participant)
- MRG-GRAMMAR (2015, participant)
- NANOREG II (2015, participant)
- ARTEMIDA (2015, participant)
- B3AFRICA (2015, participant)
- INDUCT (2016, participant)
- EVOLUTION (2016, participant)
- ISOTOPICS (2016, participant)
- RNAEDIT (2016, participant)
- EU-TOXRISK (2016, participant)
- EAVI2020 (2015, participant)
- I-PROGNOSIS (2016, participant)
- COCA (2016, participant)
- COSTREAM (2015, participant)
- HERCULES (2016, participant)
- U-PGX (2016, participant)
- ADOPT BBMRI-ERIC (2015, participant)
- EHVA (2016, participant)
- NEVERMIND (2016, participant)
- CETM (2016, participant)
- VACTRAIN (2016, participant)
- MOMENDO (2016, participant)
- GRAPHENECORE1 (2016, participant)
- PRONKJEWAIL (2016, partner)
- CHROME (2016, participant)
- CALIBRATE (2016, participant)
- CAPRI (2016, participant)
- HBP SGA1 (2016, participant)
- TRANSMIT (2017, participant)
- SYNTRAIN (2016, participant)
- MMBIO (2017, participant)
- HOME_EU (2016, participant)
- LIVE INCITE (2016, participant)
- BIGO (2016, participant)
- CAPICE (2017, participant)
- INTRICARE (2017, participant)
- TREATER (2017, participant)
- CCHFVACCINE (2017, participant)
- IMPACT TB (2017, participant)
- ESCAPE-NET (2017, participant)
- INFRAFRONTIER2020 (2017, participant)
- INSTRUCT-ULTRA (2017, participant)
- PEDCRIN (2017, participant)
- RECAP PRETERM (2017, participant)
- EUSCREEN (2017, participant)
- CROWDHEALTH (2017, participant)
- AMYPAD (2016, participant)
- MOPEAD (2016, participant)
- ESIT (2017, participant)
- BIGDATA HEART (2017, participant)
- AIPBAND (2018, participant)
- CARESYAN (2018, participant)
- NANOSTEM (2018, participant)
- COSMIC (2018, participant)
- DNA-ROBOTICS (2018, participant)
- BACK-UP (2018, participant)
- NEOSETAC (2018, participant)
- PRODEMOS (2018, participant)
- STOP (2018, participant)
- METLINK (2018, participant)
- BIORIMA (2017, participant)
- GRAPHENECORE2 (2018, participant)
- TOBEATPAIN (2018, participant)
- FOODENTWIN (2018, participant)
- ASCTN-TRAINING (2018, participant)
- V.A. CURE (2019, participant)
- ADDRESS (2019, participant)
- BONEPAINII (2019, participant)
- SYNBIOCARB (2018, partner)
- ACT (2018, participant)
- C4C (2018, participant)
- AIMS-2-TRIALS (2018, participant)
- SAPIENS (2019, participant)
- POTION (2019, participant)
- CARE (2019, participant)
- ENDPOINTS (2019, participant)
- ERINHA-ADVANCE (2019, participant)
- ONCOBIOME (2019, participant)
- RADAR-AD (2019, participant)
- DEEPHEALTH (2019, participant)
- NECESSITY (2019, participant)
- CUREX (2018, participant)
- GOV4NANO (2019, participant)
- EU-OPENSCREEN-DRIVE (2019, participant)
- FREIA (2019, participant)
- HBP SGA2 (2018, participant)
- ICEI (2018, participant)
- ARTHRITISHEAL (2019, participant)
- GOLIATH (2019, participant)
- PREFERABLE (2019, participant)
- EU-STANDS4PM (2019, participant)
- MYPAL (2019, participant)
- LIFETIME (2019, participant)
- BIOMAP (2019, participant)
- CONCEPTION (2019, participant)
- EXPERT (2019, participant)
- PERFORCE3 (2020, participant)
- CANCERPREV (2019, participant)
- 3TR (2019, participant)
- PRECODE (2019, participant)
- EUSNN (2019, participant)
- CAST (2019, participant)
- CELL2CELL (2019, participant)
- MATER (2019, participant)
- SAND (2019, participant)
- LIFECHAMPS (2019, participant)
- COMORMENT (2020, participant)
- H-WORK (2020, participant)
- CANDY (2020, participant)
- RESCUER (2020, participant)
- UNITI (2020, participant)
- QUALI-DEC (2020, participant)
- AFFECT-EU (2020, participant)
- RISCC (2020, participant)
- IP-CURE-B (2020, participant)
- MISTRAL (2020, participant)
- MAGNET4EUROPE (2020, participant)
- AND-PD (2020, participant)
- EXPANSE (2020, participant)
- EPHOR (2020, participant)
- EQUAL-LIFE (2020, participant)
- NSC-RECONSTRUCT (2020, participant)
- GRAPHENECORE3 (2020, participant)
- SPHERES (2020, participant)